losoxantrone | 88303-61-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: losoxantrone
• 英文别名: Biantrazole；6-hydroxy-14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(2-hydroxyethylamino)ethylamino]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one;hydrochloride
• CAS: 88303-61-1
• 化学式: C₂₂H₂₇N₅O₄*2ClH
• 分子量: 498.409
• InChiKey: GDNYMYIKZYXFET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.95
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  132
• 氢给体数：
  7
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 losoxantrone 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以96%的产率得到1,1-dimethylethyl [2-[5-[[2-[[(1,1-dimethylethoxy)carbonyl](2-hydroxyethyl)amino]ethyl]amino]-2,6-dihydro-7-hydroxy-6-oxoanthra[1,9-cd]pyrazol-2-yl]ethyl](2-hyroxyethyl)-carbamate
  参考文献：
  名称：

  Synthesis of Losoxantrone Metabolites Isolated from Human Urine

  摘要：

  The first regiospecific synthesis of the monoacid metabolites (2) and (3) of losoxantrone is reported. In addition, synthesis of the diacid metabolite (4) via two different routes is also described. The chemical structures of these metabolites as well as their intermediates have been fully characterized.

  DOI：

  10.3987/com-99-8641
• 作为产物：
  描述：

  洛索蒽醌 在 盐酸 作用下， 以 异丙醇 为溶剂， 反应 2.0h， 以88%的产率得到losoxantrone
  参考文献：
  名称：

  抗癌蒽吡唑类。改进了临床药物CI-937，CI-941和盐酸吡罗酮的合成

  摘要：

  据报道，用于合成大量蒽吡咯临床药物CI-937，CI-941和盐酸吡咯酮的改进方法。还报告了这些试剂和合成序列中间体的详细分析和光谱数据。

  DOI：

  10.1002/jhet.5570260117

文献信息

• Process for preparing substituted anthra[1,9-cd]pyrazol-6(2H)-ones
  申请人：Warner-Lambert Company

  公开号：US04672129A1

  公开（公告）日：1987-06-09

  An improved process for producing anthra[1,9-cd]-pyrazol-6(2H)-ones from 1,4-dichloro-5,8-disubstituted 9,10-anthracenediones. The process produces higher yields by using a new combination of protecting groups on the compounds which allows for easier and cleaner chromatographic resolution. The compounds produced have antibacterial, antifungal, antileukemic, and antitumor activity.

  一种从1,4-二氯-5,8-二取代9,10-蒽酮中生产蒽[1,9-cd]-吡唑-6(2H)-酮的改进工艺。该工艺通过在化合物上使用新的保护基组合，使色谱分离更加容易和清洁，从而产生更高的产量。所生产的化合物具有抗菌、抗真菌、抗白血病和抗肿瘤活性。
• Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
  申请人：CYTOSCAN SCIENCES, L.L.C.

  公开号：US20040052730A1

  公开（公告）日：2004-03-18

  Optical detection techniques for the assessment of the physiological state, health and/or viability of biological materials are provided. Biological materials which may be examined using such techniques include cells, tissues, organs, subcellular components and intact animals. The inventive techniques may be employed in screening of potential diagnostic and/or therapeutic agents. One or more maps of data that correspond to the optical properties of a sample may be created and viewed.

  提供了用于评估生物材料的生理状态、健康状况和/或存活能力的光学检测技术。可使用此类技术检测的生物材料包括细胞、组织、器官、亚细胞成分和完整的动物。本发明的技术可用于筛选潜在的诊断和/或治疗药物。可创建并查看与样本光学特性相对应的一个或多个数据图谱。
• Modulator of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
  申请人：——

  公开号：US20040204357A1

  公开（公告）日：2004-10-14

  The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of cancer disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis of radiopharmaceutics into cells of the kidney and the subsequent radioinduced damaging of the kidney catabolism by blocking or interfering with the association or binding of radiotherapeutics and/or radiodiagnostics to the receptor megalin, a member of the LDL-receptor family. In another aspect of the present invention, the expression of megalin is altered, in order to prevent the endocytosis and cellular internalisation of radiopharmaceutics into cells of the kidney.

  本发明广泛涉及癌症疾病的治疗、诊断和预防。更具体地说，本发明涉及通过阻断或干扰放射性治疗药物和/或放射性诊断药物与受体megalin（低密度脂蛋白受体家族的成员）的结合或结合，防止放射性药物内吞进入肾脏细胞以及随后放射性诱导的肾脏分解代谢损伤的方法和组合物。本发明的另一个方面是改变megalin的表达，以防止放射性药物内吞和细胞内化到肾脏细胞中。
• Reversal of the regioselectivity of anthrapyrazole formation. A new synthesis of losoxantrone (DUP941)
  作者：Lin-hua Zhang、Walter E. Meier、Elton J. Watson、Emily P. Gibson

  DOI：10.1016/s0040-4039(00)73069-3

  日期：1994.5

  Losoxantrone, a potent anticancer agent, has been efficiently synthesized in a 6 step process from 5-hydroxy-1,4-dichloroanthracene-9,10-dione.
• US6319682B1
  申请人：——

  公开号：US6319682B1

  公开（公告）日：2001-11-20